Related Experiment Video
Updated: Feb 21, 2026

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool
Sanjay Kalra1, A G Unnikrishnan2, Manash Baruah3
1Director, Bharti Hospital and BRIDE, Karnal, Haryana, India.
Abstract:
Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Dosage Regimens: Partial Pharmacokinetic Parameters
Secondary Active Transport
Secondary Active Transport
Dosage Regimen Designs: Nomograms and Tabulations
Dosage Regimen: Individualization

